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ABSTRACT
There are an estimated 300-500 million cases of malaria every year, resulting in
approximately 2 million deaths. Malaria mortality occurs primarily in children under the
age of five, and is resultant from the development of severe malaria. Attempts to control
P. falciparum malaria face rapidly escalating levels of resistance on two fronts: the
parasite to anti-malarial drugs, and the mosquito vector to insecticides. Despite current
prevention efforts, the global incidence of malaria continues to rise and there is a clear
and urgent need for a malaria vaccine. Malaria vaccine efforts thus far have been largely
unsuccessful in eliciting robust and long-lasting immunity. While adults living in malaria
endemic regions have not been shown to naturally develop protective immunity to
uncomplicated malaria, they do appear to develop protective immunity to severe malaria
by around the age of five, raising the possibility that a vaccine specifically targeting
severe malaria may be a more attainable goal of malaria vaccine efforts in the immediate
future. There is mounting evidence that the pathogenesis of severe malaria is directly
related to cytoadhesion and rosetting of parasitized red blood cells. The P. falciparum
protein PfEMP1, which is expressed on the surface of parasitized red blood cells, appears
to have a direct role in mediating cytoadhesion and rosetting. The DBL1α domain of
PfEMP1 specifically been implicated in these interactions, and is also one of the only
regions of PfEMP1 that is highly conserved, making it a promising target antigen for
malaria vaccine development. Here we show that immunization with recombinant
vesicular stomatitis virus vaccine vectors expressing DBL1α induce immune responses
that are able to disrupt rosetting of parasitized RBC. This response was comparable with
that seen in adults from malaria endemic regions.
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INTRODUCTION

Epidemiology and Global Impact of Malaria
Approximately 40% of the world’s population lives in areas at risk for malaria. There are
four species of Plasmodium that cause human malaria, with P. falciparum being
responsible for the greatest burden of morbidity and mortality. The WHO estimates that
there are up to 500 million cases of malaria every year, resulting in 1-2 million deaths.
Older children and adults appear to gain some degree of protective immunity that renders
them less susceptible to severe infections that carry high mortality rates, however malaria
is currently the third leading cause of death in children under five in developing
countries. Malaria is both a disease of poverty and a cause of poverty, and is a significant
barrier to economic development in malaria endemic countries. Globally, there is a
striking overlap of malaria burden and regional poverty. It is estimated that malaria is
responsible for a “growth penalty” of up to 1.3% per year in regions of high transmission,
which, over time can lead to substantial retardation of economic growth in the region1. In
addition, malaria is estimated to account for up to 40% of public health expenditures,
50% of inpatient admissions, and 50% of outpatient visits in countries with a high
malaria burden, putting an enormous strain on already overtaxed health care systems.

The transmission vector for P. falciparum is the female Anopheles mosquitos. P.
falciparum gametocytes are ingested with a blood-meal taken from an infected human.
Male and female gametocytes fuse and mature into ookinetes in the mosquito gut, and
subsequently into oocysts in the gut wall. The oocysts rupture to release sporozoites that
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migrate to the mosquito salivary glands. The sporozoites are then injected into the skin
of a new human host during the mosquito’s next blood meal. Once in the host, malaria
parasites undergo two phases of development: the liver or exoerythrocytic phase, and the
blood or erythrocytic phase. Injected sporozoites initially migrate through the
bloodstream to the liver where they infect hepatocytes. Within the hepatocytes, the
sporozoites mature into merozoites over a period of 1-2 weeks. Upon rupture of infected
hepatocytes, large numbers of merozoites are released into the blood and infect red blood
cells 2. During the blood stage of the infection, merozoites replicate asexually in RBCs
going through the trophozoite or ring form and the schizont form before the RBC
ruptures releasing many mature merozoites that can then go on to infect more RBCs,
continuing the cycle. A small proportion of merozoites mature into male or female
gametocytes after invading RBCs. The gametocytes are released into the blood stream
with the rupture of infected RBCs. They can then be consumed during a blood meal and
mature into sporozoites within the mosquito vector, eventually being transmitted to
another host.

Importance of Malaria Vaccine Development
Attempts to control P. falciparum malaria are currently facing rapidly escalating levels of
resistance on two fronts: resistance of the parasite to anti-malarial drugs, and resistance of
the mosquito vector to insecticides. Many areas of the world are seeing increasing
malaria rates due to immigration and foreign travel, in addition to changing climate
conditions that favor multiplication of the mosquito vector. Given the extremely high
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public health burden of malaria treatment in endemic areas, it seems clear that prevention
is the most cost effective approach. This is especially true because natural protective
immunity is very slow to develop, leaving individuals susceptible to repeated infections
requiring treatment. In addition, prevention would be thought to mitigate the economic
costs of malaria endemicity to a greater extent than treatment if acute attacks of malaria
can be prevented before they manifest clinically and lead to significant decreases in
current and future productivity. Major strategies for prevention include vector control,
insecticide treated bed nets, and indoor spraying of insecticides. These methods have
been in use for extended periods of time, and while they are effective, global malaria
mortality and morbidity continue to increase despite their use and there is a consensus
that a malaria vaccine is urgently needed 3. No malaria vaccine in late stage development
has demonstrated strong (>50%) protection, or a durable protection (>1 year). Much has
been learned, however, from first generation malaria vaccine development efforts that
can be applied to future efforts.

The majority of malaria vaccines currently in development are based on a very small
number of Plasmodium falciparum antigens 4. Few of these antigens have been identified
using human or primate studies, most being discovered using mouse models. The
relevance of these models is increasingly being questioned due to the non-natural host
parasite interaction seen in these models, as well as their demonstrated failure to
accurately predict human responses 5. It will be preferable for future efforts to rely on
targets that have been identified or validated in human or primate, studies.
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Experiences during clinical trials of several of the first generation malaria vaccines have
highlighted the critical importance of understanding the interplay between malaria
parasites and the immune system 4, and future vaccine efforts need to additionally focus
on exploring how to rationally shape the immune response elicited to malaria target
antigens based on our increasing understanding of the host-parasite interactions. There is
also an emerging consensus that a multi-stage, multi-antigen vaccine will ultimately be
necessary to achieve a high degree of protective efficacy6. There are a small number of
such efforts currently in early stage development, however these vaccines are likely to be
complex to execute and are likely many years away, particularly given the potential for
antigenic interference and our current lack of understanding of the requirements for an
effective adjuvant. One important, and likely more rapidly attainable, goal of a malaria
vaccine development is to improve rates of malaria mortality, particularly in children, by
specifically targeting the development of severe malaria. While immunity to
uncomplicated malaria develops very slowly and is rarely fully protective, immunity to
severe malaria appears to develop with significantly greater rapidity, possibly reflecting a
higher degree of antigenic homogeneity in the virulence factors of parasites responsible
for severe disease 7. Antigens implicated in the development of severe malaria are thus
potentially attractive vaccine candidates because they may face fewer of the difficulties
that have been encountered in eliciting protective immunity to uncomplicated P.
falciparum malaria.
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Vesicular Stomatitis Virus Vectors in Malaria Vaccine Development
A viral vector approach to a P. falciparum malaria vaccine is currently receiving a great
deal of interest 8. Vaccines based on live viruses induce life-long immunity through
induction of durable memory B and T cell responses. Such vaccines have been
responsible for extensive control or even complete elimination of viral diseases. Some
have proposed that viral vector-based vaccines may be the most promising approach to
generating protective immunity to parasites, and that the specific choice of viral vector
appears to be crucial in determining vaccine efficacy 9. While many, if not most, of the
malaria vaccines currently under development that have shown the best success
incorporate a viral vector, there has been very little effort specifically targeted at
identifying and using the most potent vaccine vectors currently available.

Vesicular stomatitis virus (VSV) is an enveloped negative strand RNA virus in the family
Rhabdoviridae. VSV has previously been demonstrated to be a highly effective vaccine
vector for multiple pathogens such as HIV-1 10 11, SARS 12, 13, RSV 14, 15, measles 16, and
Yersinis pestis 17. Vaccine vectors based on recombinant, attenuated VSV have been
used extensively as experimental vaccines and will be used in clinical trials scheduled to
begin in 2011. These experimental VSV vaccines have induced long-term immunity to
both viral and bacterial pathogens in animal models, and should be further explored for
use in parasite vaccine development.

Pathogenesis of Severe Malaria
Clinically, malaria can be broadly classified as uncomplicated or severe. Symptoms of
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uncomplicated malaria can include a cyclical fever recurring every 36-48 hours or a
continual low-grade fever, as well as anemia, malaise, arthralgias, vomiting, and rigors.
Uncomplicated malaria is important in terms of burden on health care systems and
decreasing productivity, however it is rarely fatal. Severe malaria, in contrast, is
frquently fatal if untreated. Complications of severe malaria include cerebral malaria,
severe anemia, acute renal failure, pulmonary edema, acidosis, and hypoglycemia, and
any of these complications can be fatal within days or even hours (World Health
Organization, 2000). Risk factors for severe malaria include age less than 5 years or
greater than 65 years, non-immune status, pregnancy, delay in treatment initiation, and
the presence of pre-existing medical conditions 18 19 20. A major cause of malaria
mortality, particularly in young children, is cerebral malaria resulting from occlusion of
cerebral microvascular by agglutinated parasitized red blood cells (pRBCs). Untreated
cerebral malaria is almost universally fatal, and even with treatment the mortality rate
remains around 20% 21. Surviving patients are at increased risk for developmental
delays, neurological deficits, epilepsy, and behavioral problems. Cerebral malaria is a
leading cause of childhood neurodisability in African children 21, which has significant
long-term implications for future productivity.

The development of severe malaria has been strongly linked to P. falciparum virulence
factors that mediate RBC cytoadherance and rosetting 22 23 24

25 26 27 28

. Expression of P.

falciparum proteins on the surface of parasitized erythrocytes mediates binding to the
vascular endothelium and to uninfected erythrocytes, resulting in the accumulation of
parasitized RBCs in capillary microvasculature. This is compounded by the altered

10

mechanical properties of pRBCs that cause decreased flexibility of the cell membrane,
which makes it difficult for the cell to pass through the microvasculature 29. The resultant
microangiopathic hemolytic anemia, which serves to exacerbate the pre-existent
hemolytic anemia from parasite induced rupture of pRBCs, can precipitate acute renal
failure, secondary to massive hemoglobinuria 29. The vasocclusive properties of pRBCs
also lead to tissue hypoxia, ultimately resulting in end-organ damage and other clinical
manifestations of severe malaria 29. Finally, the sequestration of pRBCs in the
microvascular stimulates cytokine production that can cause direct tissue damage 2. The
major factor mediating pRBC cytoadherence to various ligands on endothelial cells other
pRBCs has been established to be the parasite protein P. falciparum Erythrocyte
Membrane Protein-1 30.

PfEMP1 and the Development of Severe Malaria
PfEMP1 is a high molecular weight (over 200 kD) protein that is expressed on the cell
membrane of parasitized red blood cells (pRBCs). PfEMP1 is composed of several
extracellular Duffy binding-like domains (DBL 1 to 5), with one to two cysteine-rich
interdomain regions (CIDRs) distributed in between the DBL domains, a transmembrane
31

region, and an intracellular acidic segment 32 33 1. PfEMP1 undergoes extensive clonal

antigenic variation and is encoded by a multigene family of variable surface antigen 4
genes with at least 50 copies per genome 34. The most conserved regions of PfEMP1 are
located in both the N- and C-terminal domains. There is a semi-conserved head structure
that includes the DBL-1α and CIDR1α domains, and there several regions of DBL-1α are
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almost 100% conserved 1. It is thought that PfEMP1 has a central role in malaria
virulence and the development of clinically severe disease due to its key roles in
rosetting, cytoadhesion, and immune evasion 35. PfEMP1 is considered by some to be the
“Achilles heel” 36 of P. falciparum because it is responsible for so many key aspects of
malaria pathology, and is expressed on the surface of pRBCs making it vulnerable host
immune attack. This is presumably why PfEMP1 has evolved to be highly polymorphic
and demonstrates such extensive clonal antigenic variation.

The region of PfEMP1 mainly responsible for mediating cytoadhesion is thought to be
the extracellular N-terminal adhesive domain DBL1α 37 38, which is relatively conserved
compared to other PfEMP1 adhesive domains 30. In studies using both rats 39 40 and
primates 40, it has been shown that anti-DBL1α antibodies can disrupt preformed rosettes
and block cytoadhesion in vivo 39. DBL1α expressed in recombinant Semiliki forest
virus vectored vaccine induced antibodies that prevented cytoadhesion and disrupted
rosettes in a mouse model 39. More importantly, these associations have been validated in
human studies. The presence of antibodies against PfEMP1 have been associated with
protection against severe disease in various studies of populations living in malaria
endemic areas 41 28 27. For example, in a study in Gambia, 88% of children with
uncomplicated malaria had anti-rosetting antibodies compared to the 22% of children
with severe malaria that had anti-rosetting antibodies 28.
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STATEMENT OF PURPOSE

The vast majority of malaria mortality is attributable to complications of severe malaria.
There is compelling evidence that the cytoadhesive properties of pRBCs are a key factor
determining the development of severe malaria, and has been linked to the expression of
PfEMP1 on the surface of pRBCs. While immunity to uncomplicated malaria develops
very slowly or not at all, immunity to severe malaria appears to develop with
significantly greater rapidity, possibly reflecting a higher degree of antigenic
homogeneity in the virulence factors of parasites responsible for severe disease 7.
Generating protective immunity to severe malaria may be a more immediately achievable
goal than immunity to uncomplicated malaria as that PfEMP1 variants of the severe
subtypes tend to be more immunogenic 40, and individuals develop protective immunity
to severe, but not uncomplicated, malaria after natural infection. PfEMP1 has been
validated as a potential target antigen in both animal and human models. The DBL1α
domain of PfEMP1 may be a promising vaccine target to reduce morbidity and mortality
from severe malaria. DBL1α is one of the few highly conserved regions of PfEMP1, and
it appears to be a region of PfEMP1 that is directly responsible for mediating
cytoadhesion and rosetting 42 37. In addition, it is expressed on the surface of pRBCs
making it vulnerable host immune attack as opposed to many malaria antigens, which are
sequestered in RBCs making them less vulnerable to both antibody and cell mediated
immunity.
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The first goal of the proposed experiments is to evaluate vesicular stomatitis virus vectors
as a platform for a vaccine incorporating the DBL1α domain of PfEMP1. The second
goal of the proposed experiments is to evaluate the effectiveness of VSV vectors
expressing DBL1α in disrupting rosette formation of pRBCs.

Aim 1. Construct and characterize VSV vectors expressing the P. falciparum
DBL1α domain of PfEMP1 (VSV-mDBL1α).
This aim will determine if VSV vectors are able to induce expression of an
antigen constructed from the the P. falciparum protein PfEMP1 and the PfEMP1
functional domain DBL1α.

Aim 2: Test the effectiveness of VSV-mDBL1α vectors in a rosette disruption assay.
This aim will determine if the constructed VSV-mDBL1α vectors are able to
induce immune responses in mice that are able to decrease or disrupt rosette
formation of human pRBCs.
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METHODS

Plasmids
We designed a codon-optimized 1.7kb gene construct encoding the PfEMP1 N-terminal
sequence (NTS, 67aa), DBL1α domain (348aa), transmembrane region (TM, 36aa), and
acid-terminal sequence (ATS, 59aa). The VSV-G signal sequence (16aa) was added to
the N-terminus and a cMyc tag (11aa) was added to the C-terminus (Figure 1). Upstream
XhoI and downstream NheI sites were introduced to allow for directional cloning into
VSV vectors. The gene product was cloned into the fifth position of VSV vectors
encoding either the Indiana or New Jersey serotype G-proteins to make VSV-mDBL1α
(Figure 2).
*All of the above experiments were preformed by the author, except for the
synthesis of the DBL1α gene construct with was preformed by the company MrGene.

Recombinant viruses
BHK-21 cells were grown to 50% confluence and infected with recombinant vaccinia
virus expressing T7 RNA polymerase and a multiplicity of infection (MOI) of 10. The
cells were incubated for 1 h in serum-free Dulbecco's modified Eagle's medium
(DMEM). The cells were then co-transfected with the plasmid expressing the
recombinant VSV anti-genome with expression vectors for the VSV N, P, and L proteins
under the control of a T7 promoter. Supernatants were collected 40 hours posttransfection, filtered through a 0.2µm-pore filter to remove vaccinia virus, and passaged
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onto fresh BHK-21 cells. Medium was collected immediately after cytopathic effects
were observed (~48 hours) and filtered through a 0.1µm-pore filter. Recombinant VSVDBL1α was then plaque purified and expanded, and the VSV- DBL1α was stored at
−80°C. Titers were determined on thawed samples to be 2.5x108.
*All of the above experiments were preformed by the author.

Detection of DBL1α expression
Immunoflorescence studies were preformed using BHK-21 cells infected with VSVDBL1α (MOI of 10), with uninfected and wild type VSV-infected cells used as controls.
Medium was collected 6h after infection, cells were washed with phosphate-buffered
saline (PBS) and lysed with 2× SDS sample buffer. Proteins were separated on a 10%
SDS gel, transferred to a nitrocellulose membrane, probed with anti-cMyc antibody, and
detected with secondary antibody using chemiluminesence. The sample was also
incubated with PNGase in glycoprotein denaturing buffer for 10 minutes at 100°C and
then for one hour at 37°C in order to deglycosylate the protein.

For immunofluorescence microscopy, BHK-21 cells were grown on glass coverslips and
infected with VSV-DBL1α (MOI of 10), with uninfected and VSV-infected cells as
controls. After 5 hours, cells were fixed with 2% paraformaldehyde and then blocked for
1 hour in PBS containing 10% fetal bovine serum. Cells were then incubated with either
anti-cMyc antibody (Santa Cruz Biotechnology; 1:50) or anti-VSV-G antibody (1:200)
for 30 min at 37°C. Cells were washed with PBS following incubation with primary
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antibody and then incubated with Alexa Fluor 488-labeled goat anti-mouse secondary
antibody (Invitrogen; 1:1,000) for 30 min at 37°C. After washing, cells were mounted
onto microscope slides with ProLong Gold antifade reagent containing DAPI (4′,6diamidino-2-phenylindole; Invitrogen). A Nikon Eclipse 80i fluorescence microscope
equipped with a Nikon Plan Apochromat 40x or 60X oil objective and a Photometrics
CoolSnap camera was used to capture images.
*All of the above experiments were preformed by the author.

Immunizations and sera collection
Female Balb/c mice at 10 weeks of age were purchased from Charles River (Wilmington,
MA) and housed at the Yale University School of Medicine animal facilities. All
experiments were performed in accordance with Yale Institutional Animal Care and Use
Committee-approved procedures. Single intramuscular (i.m.) inoculations of VSVmDBL1α (108 PFU) were administered in a 50-µl volume. A VSV vector expressing
HIV gag (VSV-41g, 108 PFU) was used as a control. All priming injections were
preformed with the VSV-Indiana strain. Boost inoculations were preformed 30 days
post-prime with the VSV-New Jersey strain of both VSV-DBL1α (108 PFU) and VSV41g (108 PFU). Sera were collected at Day 0 (pre-prime), Day 30 (pre-boost), and Day
60.
*All of the above experiments were preformed by the author except for sera
collection, which was preformed by the Yale Animal Research Facility technicians.
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Rosette disruption assay
Rosette disruption assays were performed using the DBL1α domain from the highly
virulent FCR3S1.2 strain of P. falciparum. A 25µl volume of FCR3S1.2 culture (5%
hematocrit, with an 80% rosetting rate) was mixed with an equal volume of sera from
immunized animal at three different dilutions (1:5, 1:10 and 1:20) and incubated at 37 °C
for 1 h. Aliquots were then mixed with 1µl of ethidium bromide (0.5µg/ml) and the
percentage of mature pRBCs in rosettes (defined as the binding of two or more labeled
RBCs) was examined using fluorescent microscopy.
*All of the above experiments were performed by collaborators from the lab of
Mats Wahlgren at the Swedish Institute for Infectious Disease Control in Stockholm,
Sweden.
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RESULTS

Construction mDBL1α gene and recovery of VSV vectors expressing mDBL1α
In order to generate effective immune responses to target antigens derived from PfEMP1,
it is thought that there must be expression of the antigen at the cell surface 39. Due to the
size and significant variability of PfEMP1, expression of the full-length protein at the cell
surface for use as an immunogen is not feasible. For this reason, Chen et al 39 introduced
the concept of creating a ‘mini’ PfEMP1 gene construct that could be used to express
individual functional domains of the PfEMP1 protein being employed as target antigens
at the cell surface by incorporating PfEMP1 structural domains. The construct we
created using this model, mDBL1α (Figure 1), consists of the NTS (67aa), the DBL1α
domain (348aa), the transmembrane region (24 aa) and part of the ATS-domain (59aa).
The VSV signal sequence (16aa) was inserted upstream to the NTS in order to target the
protein into the exocytic pathway and potentially to the cell surface, and a cMyc tag
(EQKLISEEDL) was inserted downstream of the ATS to facilitate detection of the
protein. Chen et al did not find a significant effect on immunogenicity due to the
presence or absence of the NTS, however others 43 have found that the presence of the
NTS upstream to the DBL1α domain significantly increased the ability to induce an
antibody response that disrupts rosetting of pRBCs. The DNA sequence encoding this
protein was synthesized (GeneMan) with upstream and downstream cloning sites.
mDBL1α was inserted into VSV vectors between the VSV-L and VSV-G proteins
(Figure 2), and successful cloning was verified by restriction digest. Recombinant VSVmDBL1α particles were generated in BHK21 cells at titers of 108/ml. Cloning of the
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mDBL1α gene into VSV and virus recoveries were performed for both vectors
expressing the Indiana (I) and New Jeresy 44 44 serotype G-proteins for use in a primeboost inoculation regimen. Neutralizing immune responses directed at the VSV vector
induced by the priming vaccination can be avoided by switching to a G-protein from a
different VSV serotype for the boost vaccination 6.

Figure 1. Schematic representation of the structure of the mDBL1α construct derived
from PfEMP1 of the highly virulent FCR3S1.2 strain of P. falciparum. The N-terminal
sequence (NTS) and DBL1α domain from the PfEMP1 gene were joined to a sequence
encoding the PfEMP1 transmembrane region 31 and portion of the acid terminal sequence
32
. The vesicular stomatitis virus G-protein signal sequence (VSV SS) was inserted
upstream of the NTS to target the protein to the exocytic pathway. A cMyc tag was
inserted downstream of the ATS to facilitate detection of the gene product.

20

Figure 2. Sequence of mDBL1a. DNA sequence is shown on the top line in the 5’ to 3’
direction. Amino acid sequence is shown on the bottom line. Regions shown in Figure 1
are labeled.
21

A

B

Figure 3. Insertion of mDBL1α into the vesicular stromatitis virus (VSV) genome.
(A) Schematic representation of the VSV-mDBL1α genome. The site of mDBL1α gene
insertion and gene order are shown in the 3′ to 5′ direction on the negative strand RNA
genome. Red arrows indicate the restriction enzyme sites used for cloning the mDBL1α
DNA. VSV-G is indicated as either the I or NJ serotypes. (B) Vector map of pVSVmDBL1α. XhoI and NheI sites used for cloning are shown.
22

Expression and cell localization of DBL1α
Immunoflorescence microscopy performed to examine expression and localization of cMyc tagged mDBL1α. The results showed that BHK21 cells infected with VSVmDBL16 expressed mDBL1α (Figure 4c). Anti-cMyc antibodies did not cross react with
uninfected cells or with cells infected with wild-type VSV (Figures 4a and 4b). VSVmDBL1α infected cells also expressed VSV-G protein (Figure 4d). Figure 3e shows
VSV-mDBL1α infected cells stained with anti-cMyc antibodies at 60x magnification.
Expression of mDBL1α at the cell surface was not detected using immunoflorescence
microscopy. The majority of expression appeared to be in a reticular ER-like pattern.
Western blot analysis on whole cell extracts of infected cells demonstrated a the presence
of a ~62kDa protein with the mobility expected of mDBL1α in cells infected with VSVmDBL1α, but not in control cells infected with wild type VSV (Figure 5). DBL1a has 3
predicted sites for N-linked glycosylation 45. If mDBL1α progressed to the secretory
pathway, the protein should have been glycosylated. Therefore, to determine whether
mDBL1α did enter the secretory pathway, we treated the protein with an N-glycosidase.
After glycosidase treatment, a mobility shift was seen, with a sharper band observed for
the deglycosylated protein (Figure 5), suggesting that mDBL1a was successfully targeted
to the secretory pathway.
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Figure 4. Indirect immunofluorescence microscopy of mDBL1α and VSV-G protein in
cells infected with VSV-mDBL1α and wild type VSV (wtVSV). (a) Uninfected BHK21
cells stained with anti-cMyc antibodies (40x objective). (b) BHK21 cells infected with
wtVSV and stained with anti-cMyc antibodies (40x objective). (c) BHK21 cells infected
with VSV-mDBL1α and stained with anti-cMyc antibodies (40x objective). (d) BHK21
cells infected with VSV-mDBL1α and stained with antibodies recognizing VSV-G
protein (40x objective). (e) BHK21 cells infected with VSV-mDBL1α stained with anticMyc antibody (60x objective).
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Figure 5. Western blot of mDBL1α. Western blot analysis was performed on whole cell
extracts prepared from BHK-21 cells infected with either VSV-mDBL1a or wild type
VSV as a control and probed with anti-cMyc antibody. Samples were also cleaved to
remove N-linked glycans. (VSV-mDBL1α + PGNase).

Immunization with VSV-DBL1α reduces rosetting of human pRBCs
After prime-boost immunization with VSV-mDBL1α, sera of immunized mice dosedependently disrupted rosettes formed by human RBCs infected with the highly virulent
FCR3S1.2 strain of P. falciparum (Figure 6a). Immunization with VSV-mDBL1α
generated a response that reduced rosetting by 58% (Figure 6b). The differences in the
mean rosette disruption rates between the sera of mice immunized with VSV-mDBL1α
and mice immunized with the control vector VSV-41g were statistically significant,
P<0.01 (Students unpaired T-test).
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Figure 6. Means of rosette-disrupting activity of the sera generated by the prime-boost
immunization with VSV-mDBL1α in mice. Sample of rosetting FCR3S1.2 (rosetting rate
of >80%) was mixed with sera diluted from 1:5 to 1:20 and the rosetting rate was scored
in incident UV-light. (a) Dose response inhibition of rosetting by serum from mice
immunized with VSV-mDBL1α. (b) Sera from mice immunized with VSV-mDBL1α
showed significantly (P<0.01, Students unpaired T-test) greater rosette-disruption activity
than serum from mice immunized with the control vector VSV-41g (VSV-control).
Baseline responses are shown at Day 0, post-prime responses were measured at Day 30,
post-boost responses were measured at Day 60.
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DISCUSSION
Immunization with VSV-mDBL1α induces a robust anti-rosetting response
We have shown that immunization with VSV vectors expressing the DBL1α domain of
the P. falciparum protein PfEMP1 generates an immune response that is able to disrupt
rosette formation in pRBCs. Sera of mice immunized with VSV-mDBL1α were able to
reduce rosetting by 58%. For comparison, a serum pool from adults living in a malaria
hyperendemic region has previously been shown to produce a 60% reduction in rosetting
40

. While older children and adults from malaria endemic areas do not develop complete

protective immunity to uncomplicated malaria, they appear to develop robust immunity
to severe malaria, and malarial mortality is rate after the age of 5 in endemic areas.

Rosette disruption assay results obtained with VSV-mDBL1α vectors compare favorably
with results from other studies using DBL1α as a target antigen. Chen et al., 2004
vaccinated mice with a DBL1α construct (DBL1α-TM-ATS) expressed in Semliki Forest
Virus (SFV) vectors, and showed a 40% reduction in rosetting 39. Improved rosette
disruption seen with VSV-mDBL1α vectors may be related to the viral vector used to
express DBL1α, but may also be related to expression of the NTS as that a recent article
has show optimal immunogenicity with NTS-DBL1α 43. In addition, the study by Cheng
et al. primed with SFV-DBL1α but boosted with recombinant protein in combination
with complete Freunds adjuvant rather than boosting with a second round of viral vector.
Moll et al (2007) similarly showed 40% rosette disruption using DBL1α expressed in
SVF vectors in monkeys 40. In this study, vaccinations were given with one prime and
two boosts with SFV-DBL1α particles, and an additional boost with DBL1α recombinant
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protein. It does not appear that boosting with additional rounds of viral vectors as
opposed to solely recombinant protein improved rosette-disruption ability, however it is
difficult to directly compare as that this study was done in primates rather than rodents.

Mini-PfEMP1 expression in mammalian cells
Codon optimized ‘mini’ PfEMP1 consisting of the structural regions of the PfEMP1
protein (the NTS, TM, and ATS regions) and the functional DBL1α domain responsible
for cytoadhesion were used in this study in an attempt to maximize cell surface
expression of DBL1α. The mDBL1α gene construct was codon optimized because there
are significant differences in protozoan and mammalian protein synthesis, with the
plasmodium genome containing a high A/T content as well as frequent lysine and
arginine repeats, and codon-optimization has been shown to significantly increase the
level of expression of P. falciparum antigens in mammalian cells 8 46 47.

The VSV signal sequence was added to the N-terminal end of mDBL1α in order to target
mDBL1α to the exocytic pathway. The glycosylation of mDBL1α suggests that it was
present in the secretory pathway, however the immunoflorescence microscopy studies
show mDBL1α expression in an ER-like pattern, which could indicate possible problems
with protein folding and transport. Historically, there have been reports of poor
processing and suboptimal transport of Plasmodial surface proteins in mamallian cells,
and it has been suggested that replacement of the Plasmodial GPI signal sequence with a
mammalian sequence would improve the immunogenicity of antigens that require cell
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surface expression 48. The effect of using a VSV signal sequence on surface expression is
unclear from these experiments as that no direct comparisons can be made. It has been
thought that expression of DBL1α at the cell surface is important to the generation of
anti-rosetting antibodies 35. The induction of a robust anti-rosetting response by VSVmDBL1α vectors, despite their apparent failure to induce surface expression of DBL1α,
suggests that cell surface expression is not necessarily requisite to generating a robust
anti-rosetting response.

Since VSV-DBL1α was observed to result in production of a glycosylated protein
product, a future avenue for exploration to improve VSV-mDBL1α immunogenicity
might be to delete N-glycosylation sites. It has been reported that N-glycosylation of
some malaria antigens decreases the strength of the immune response directed toward
those antigens 49 50, and it is currently being studied whether removal of N-glycosylation
sequences will improve immune responses 8.

Advantages of vesicular stomatitis vectors in malaria vaccine development
VSV not previously been used in malaria vaccine development, but VSV has several
attributes that could make it particularly well suited for use in a malaria vaccine strategy.
VSV infects humans very rarely because humans are not a natural host for VSV. As
such, there is extremely low seroprevalence in the human population world-wide. This is
in contrast to viral vectors being used for malaria vaccines such as adenovirus, which is
estimated to have a global seropositivity of up to 50%, with some estimates reaching up
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to 90% in developing countries. VSV vectors are also able to be administered
intranasally. A mucosal route is much more feasible than a parenteral route for large
scale administration in developing countries due to the lack of a need for needles –
which, when in short supply, can contribute to the spread of blood borne pathogens
through re-use – as well as the need for a trained healthcare professional to administer the
vaccine. The enormous success of the live polio vaccine was due in part to the fact that it
is administered via a non-injectible route. Multiple studies with malaria parasites have
indicated that mucosal vaccination is effective at inducing protective immune responses
32 51 52

.

A future possibility for maximizing effectiveness of VSV-vectored malaria vaccines
could be to use them in a heterologus regimen with a second viral vector, particularly
with regard to improving durability of the immune response. Multiple studies of viral
vectored malaria vaccines have shown that heterologus prime-boost regimens (AB or
BA) are more effective than homologous prime boost (AA or BB), and recent
studies have demonstrated the superiority of an alternating heterlogous regimen
(ABA) in maximizing immune response durability 53 54. One study using a
combination of MVA and Fowlpox vectored malaria vaccines demonstrated that while
the responses to heterologous prime-boost vaccination fell to pre-vaccination levels after
270 days, the response to the heterologous alternating vector regimen remained at 84% of
the peak response 54. One way of moving forward might be to combine VSV-vectored
DBL1α vaccine with a Semliki Forest Virus vectored vaccine that also expresses DBL1α.
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Clinical significance of rosette disruption in severe malaria
Rosette disruption assays establish the functional ability of immune sera to prevent
cytoadhesive interactions that have been shown to be associated with the
pathophysiology of severe malaria. Therapeutic interventions that target rosetting may
therefore have potential to decrease the global burden of severe malaria 55 56. Human
genetic studies have shown that RBC polymorphisms that reduce rosetting, such as
complement receptor 1 deficiency 37 and blood group O 23, confer protection against
severe malaria 57 58 possibly by reducing the vaso-occlusive effects of rosetting 59. The
association of rosetting with severe malaria, taken with the protective effects of human
polymorphisms that reduce rosette formation, support a direct role of rosetting in the
pathogenesis of severe malaria. Further support is provided by the observation that the
presence of antibodies against PfEMP1 is associated with protection against severe
malaria in various studies of populations living in malaria endemic areas 41 28 27.

Antibodies to DBL1α from the FCR3S1.2 strain of P. falciparum have been shown to be
cross-reactive with multiple rosetting strains of highly virulent P. falciparum 40. A
vaccine that that incorporates targets antigens from the more virulent strains of P.
falciparum that are specifically related to the development of severe malaria hold promise
of decreasing malaria mortality, the vast majority of which is secondary to the
development of severe malaria. This will mainly affect children under 5, in whom the
vast majority of severe malarial mortality is observed. In addition, such vaccines could
be an important component of a traveler’s vaccine as that travelers are also at increased
risk of developing severe malaria due to their lack of previous exposure and non-immune
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status. Such a vaccine will likely not be directly effective in preventing morbidity related
to uncomplicated malaria. However it may be able to make a unique contribution
towards the eventual development of a vaccine that confers protection to uncomplicated
malaria due to the important role of PfEMP1 in parasite immune evasion and
immunomodulation.

Failure to induce durable immunologic memory has been one of the most significant
obstacles to the success of virtually every malaria vaccine effort to date. The interactions
between P. falciparum and the mammalian immune system are extremely complex. Not
only has the parasite developed sophisticated immune evasion mechanisms, there is
compelling evidence that it actively induces host immune suppression. Some of the
difficulties in malaria vaccine efforts encountered thus far in inducing a durable immune
response may be partially addressed by designing vaccines with these interactions in
mind. In general, malaria vaccine efforts have thus far focused almost exclusively on the
antigen selection process – which is understandable given that the Plasmodium genome
contains over 5,000 genes. Interestingly, however, the genome of P falciparum contains
more genes related to host immune evasion and immune suppression than it does
enzymes. Experience during clinical trials of several of the first generation malaria
vaccines has highlighted the critical importance of adjuvant selection to the ability of a
vaccine to induce a durable immune response, or even any immune response at all 4. This
suggests that the specific immune microenvironment at the time of vaccination may have
an importance approaching that of the actual choice of target antigen(s). Rather than
simply continuing the strategy of attempting to identify more antigens, future vaccine
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efforts need to additionally focus on exploring how to rationally shape the immune
response elicited to malaria target antigens based on our increasing understanding of the
interactions of the malaria parasite with the host immune system, and targeting PfEMP1
could play an important role in this process.

Future directions: PfEMP1 and parasite induced immune modulation and evasion
Malaria parasites have evolved various mechanisms to evade host immune defenses: 1)
The most basic mechanism of immune escape is the intracellular parasitism of RBCs,
allowing the parasites avoid humoral immune responses while simultaneously evading
recognition by CD8+ T-cells due to the lack of expression of MHC I molecules on the
RBC surface. 2) There is a high degree of antigenic polymorphism in malarial parasites,
and the low immunogenicity and high heterogeneity of malaria antigens is thought to
drive the immune system to respond to too many targets 60. Many of these targets contain
tandem repeats that provide immunodominant B-cell epitopes, potentially masking the
critical epitopes for protective immunity by affecting the affinity maturation of antibodies
and inducing T-cell independent B-cell activation 36. 3) The expression of PfEMP1 on
pRBCs allows parasites to adhere to the vascular endothelium, protecting them from
splenic clearance. 4) Given the critical importance of PfEMP1 to essential parasite
functions such as adhesion, as well as its’ vulnerable location exposed on the surface of
pRBCs, PfEMP1 has evolved to be extremely polymorphic as well as to exhibit a high
degree of clonal antigenic variation. The var gene encoding PfEMP1 is present at over
50 loci in the plasmodium genome, and blood stage parasites are able to switch
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expression between these various loci resulting in antigenically distinct waves of
parsitemia that effectively allow evasion of the primary antibody response 33.

In addition to immune evasion mechanisms, malaria parasites appear to have the ability
to actively induce host immune suppression 36 61. Patients with active malaria infection
often show reduced immune responses not only to malaria parasites, but to other,
unrelated, infectious organisms as well as vaccines 62. This active immune suppression
during infection could make it difficult for the host to develop and sustain robust
protective immunity. This is seen both in the long latency to acquiring protective
immunity in individuals in malaria endemic areas, as well as the difficulties encountered
thus far in inducing durable immune responses with vaccines. Recently it has been
demonstrated that PfEMP1 can bind to B-cells and dendritic cells, an interaction that has
the potential to actively interfere with the host immune system during infection 35.
PfEMP1 has been shown to inhibit the maturation of antigen presenting cells in vitro 63,
which could lead to impaired T-cell responses. This interaction with dendritic cells
induces upregulation TGF-β as well as induction of T-regulatory cell activation and
proliferation. PfEMP1 has additionally been shown to suppress PBMC production of
IFN-γ in vitro by up to 20-fold 6. A clear consensus has not yet been achieved as to the
domains of PfEMP1 that are critical to its immune evasion properties. The most recent
evidence indicates that – in contrast what has been previously believed – the interaction
of PfEMP1 with APCs occurs independently of a direct interaction of the CIDR1 domain
with host CD36, and instead may involves the DBL domain 64.
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Conclusions
The critical role of PfEMP1 in the development of severe malaria and in P. falciparum
immune evasion make it an important vaccine candidate. The majority of PfEMP1 is
highly polymorphic with the major exception being the DBL-1α domain, regions of
which are almost 100% conserved 1. There appears to be a higher degree of antigenic
homogeneity in the virulence factors of parasites responsible for severe disease 7, and
cross-reactivity to DBL1α appears to occur between a number of highly virulent strains
of P. falciparum. There is compelling evidence that the DBL1α domain is responsible
for the cytoadhesive and rosetting properties of pRBCs that are central to the
development of severe malaria, and may be involved in important aspects of parasite
immune evasion. There is evidence from numerous human studies, as well as rodent and
primate studies, that strongly support the potential utility of DBL1α as a target antigen,
and it is hoped that immunization with vaccine incorporating DBL1α could alleviate
some of the burden of severe malarial mortality in the future.

VSV vectors have been shown to be highly effective in inducing potent immune
responses in a number of other diseases, and may also be well-suited to malaria vaccine
development. We have shown that immunization with DBL1α expressed in VSV vectors
induces anti-rosetting activity comparable to that of immune sera from adults living in
malaria hyperendemic regions. Future studies should look toward establishing whether
the immune response durability of VSV vectored DBL1α vaccines might be optimized by
incorporating them into an alternating heterologous prime-boost regimen with other viral
vectored DBL1α vaccines such as the SFV-DBL1α vaccine currently in development. In
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addition, it future studies should examine whether incorporation of DBL1α into a multiantigen vaccine targeting uncomplicated malaria might improve vaccine efficacy by
interfering with parasite immunomodulation and immune evasion strategies that may be
partially responsible for difficulties encountered with current vaccine efforts.
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